The Q3FY19 numbers were operationally in-line with I-direct estimates, with revenues up 15.0% YoY to | 2377.1 crore (I-direct estimates: | 2436.5 crore). Revenues in the pharma business grew 28.8% YoY to | 1418 crore (I-direct estimate: | 1497 crore) on the back of strong growth across segments. Life science ingredients (LSI) revenues fell 2.9% YoY to | 899 crore (I-direct estimate: | 865 crore) EBITDA margins improved 59 bps YoY to 20.8% (I-direct estimate: 19.8%) mainly due to an improvement in gross margins. EBITDA...